ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: The melanocortin 1 receptor (MC1-R) is expressed by monocytes and macrophages, where it exerts anti-inflammatory actions on stimulation with its natural ligand α-melanocyte-stimulating hormone. The present study was designed to investigate the specific role of MC1-R in the context of atherosclerosis and possible regulatory pathways of MC1-R beyond anti-inflammation.
T
he melanocortin system, consisting of melanocyte-stimulating hormones (α-, β-, and γ-MSH) and their cognate receptors, regulates a variety of physiological functions, ranging from skin pigmentation to centrally mediated energy balance control. 1, 2 At the cellular level, the biological actions are mediated by a family of 5 G-protein-coupled melanocortin receptors, called melanocortin 1 receptor (MC1-R) to melanocortin 5 receptor, which all have distinct tissue distribution and functional properties. MC1-R was the first receptor member to be cloned and is known to be an integral regulator of skin pigmentation. 3, 4 Over the past years, it has become evident that MC1-R signaling exerts not only melanogenesis in the skin but also immunomodulatory effects through its wide expression in the cells of the immune system such as monocytes and macrophages. 1, 5, 6 However, because macrophages also express melanocortin 3 receptor, which is proposed to be the dominant receptor over MC1-R for conveying melanocortin-induced anti-inflammation, [7] [8] [9] the question arises of whether MC1-R is dispensable in this regard or whether it may exhibit additional asyet unknown functions in macrophages. To address these questions, we investigated the role of MC1-R in the context of atherosclerosis with particular focus on cholesterol metabolism, which is a crucial function of macrophages.
Atherosclerosis is a chronic inflammatory disease of large and medium-sized arteries that involves both the innate and adaptive immune systems. 10, 11 In particular, monocytes and their descendant macrophages are the dominant effector cells responsible for disease initiation and progression. [12] [13] [14] Hypercholesterolemia and increased plasma levels of the principal atherogenic lipoprotein, low-density lipoprotein (LDL), promote cholesterol trapping and accumulation in the arterial intima, which eventually attracts monocytes to the scene. Under oxidative conditions, LDL becomes modified, enabling its recognition and uptake by macrophages via scavenger receptors. When macrophages engulf oxidized LDL (oxLDL), it directly triggers proinflammatory signaling pathways and drives the transformation of these cells into foam cells, which in turn amplify the inflammatory process and aggravates atherosclerosis. 15 This detrimental cascade is counterregulated by reverse cholesterol transport, which facilitates the clearance of excess cholesterol from macrophages and its subsequent transport to the liver for excretion. The first steps of reverse cholesterol transport are mediated by the ATP-binding cassette transporters ABCA1 and ABCG1, which promote cholesterol efflux onto high-density lipoprotein (HDL) particles and its main protein constituent apolipoprotein A1 (ApoA1). Consequently, finetuning the balance between cholesterol uptake and efflux protects against maladaptive immune responses, foam cell formation, and ultimately atherosclerosis.
Given the previously identified expression of MC1-R in macrophages, the major cell type within atherosclerotic plaques, we first aimed to characterize MC1-R expression in human and mouse atherosclerosis. We confirmed colocalization of MC1-R expression with macrophages in atherosclerotic lesions and found a strong positive correlation with the expression of reverse cholesterol transporters rather than with inflammatory markers. Thus, we hypothesized that MC1-R signaling is involved in the regulation of cholesterol transport in macrophages.
METHODS
Detailed methods are available in the online-only Data Supplement.
Clinical Perspective
What Is New?
• Although the expression of melanocortin 1 receptor (MC1-R) and its role in modulating inflammatory responses in macrophages have been previously established, we here identify a novel regulatory function for MC1-R in macrophage cholesterol transport.
• Activation of macrophage MC1-R promotes the clearance of excess cholesterol from macrophages by increasing the expression of ATP-binding cassette transporters ABCA1 and ABCG1, which initiate macrophage reverse cholesterol transport.
• Moreover, MC1-R signaling inhibits the uptake of oxidized low-density lipoprotein.
• In vivo, MC1-R expression localizes in atherosclerotic plaque macrophages and correlates with the levels of ATP-binding cassette transporters ABC1 and ABCG1.
What Are the Clinical Implications?
• The removal of excess cholesterol from macrophage-derived foam cells in atherosclerotic plaques is the critical first step of reverse cholesterol transport, which facilitates the transport of peripheral cholesterol to the liver for excretion.
• Promoting macrophage reverse cholesterol transport limits the progression of atherosclerosis and may ideally complement other lipid-lowering therapies to control for the residual risk that is often present in medically treated patients with atherosclerotic disease.
• Therefore, the identification of MC1-R in lesional macrophages and its role in regulating reverse cholesterol transport, combined with the established anti-inflammatory effects of MC1-R, could serve as an attractive new approach for preventing atherosclerosis.
) mice were randomly assigned to receive daily intraperitoneal injections of either PBS (vehicle) or the selective MC1-R agonist MSG606 (1 mg/kg) 16 and were fed a cholesterol-rich high-fat diet (HFD) for 4 weeks. All animal experiments were approved by the local ethics committees and conducted in accordance with the institutional and national guidelines for the care and use of laboratory animals.
Human Endarterectomy Samples
TVS (Tampere Vascular Study) endarterectomy samples were obtained from carotid arteries, abdominal aortas, and femoral arteries as previously described. 17, 18 The left internal thoracic artery samples, obtained during coronary artery bypass surgery, served as controls. Gene expression was analyzed from carotid (n=29), abdominal aortic (n=15), and femoral (n=24) plaques and atherosclerosis-free left internal thoracic arteries (n=28). The expression levels were analyzed with Illumina HumanHT-12 v3 Expression BeadChip (Illumina). 18, 19 The study was approved by the Ethics Committee of Tampere Hospital District and conducted according to the declaration of Helsinki, and the study subjects gave informed consent.
Bone Marrow-Derived Macrophages
Bone marrow cells were cultured in RPMI-1640 medium supplemented with 10% FCS, penicillin (100 U/mL), streptomycin (100 μg/mL) (all Gibco Life Technologies), and 10% filtered L-929 cell-conditioned medium as a source of macrophage colony-stimulating factor. Experiments were done on differentiated BMDMs 7 to 10 days after plating.
Flow Cytometry Analysis of BMDMs
To assess the uptake of oxLDL, BMDMs were treated with Dil-conjugated oxLDL (5-20 μg/mL; Alfa Aesar) for 4 hours and then analyzed with FACS Canto II (BD Biosciences). To quantify the expression of CD36 on the cell surface, BMDMs were stained with antibodies against CD36 PE-Cy7 (clone HM36) and CD11b APC (clone M1/70). Proliferation and cell cycle status were assessed after staining with Ki67 FITC (clone SolA15) and the nuclear DNA dye 7-aminoactinomycin D.
Cholesterol Efflux Assay
BMDMs were incubated with complete medium containing [ 3 H]-cholesterol (1 μCi/well; PerkinElmer) and oxLDL (20 μg/mL; Alfa Aesar) for 24 hours and thereafter equilibrated for 18 hours in RPMI medium containing 0.2% BSA. When stated, the cells were treated with α-melanocyte-stimulating hormone (α-MSH) or the selective MC1-R agonists during the equilibration phase. The equilibrated BMDMs were then incubated for 6 hours with serum-free RPMI medium containing 0.2% BSA and ApoA1 (15 μg/mL; Sigma) or HDL (50 μg/mL; Millipore) to facilitate cholesterol efflux.
Western Blotting
BMDMs were lysed with radioimmunoprecipitation assay buffer, size-fractioned by SDS-PAGE, and then transferred to nitrocellulose membranes. 20 After the blocking step, membranes were probed with primary antibodies followed by detection with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence. Target protein expression was normalized to GAPDH or β-actin to correct for loading.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted (peqGold Trifast and Total RNA kit; Peqlab) and reverse transcribed (PrimeScript RT kit, Clontech). Real-time polymerase chain reaction was performed with the 7900HT Sequence Detection System (Applied Biosystems) with predesigned primer and probe mix (Life Technologies) or primer sequences given in Table I in the online-only Data Supplement. Target protein expression was normalized to hypoxanthine phosphoribosyltransferase, and the fold induction was calculated with the comparative ΔCt method and presented as relative transcript levels (2
−ΔΔCt
).
Histology and Immunohistochemistry
Aortic roots were cut in 5-μm-thick serial cryosections and stained with Oil Red O to quantify lesion size. For immunohistochemistry, sections were incubated with primary antibodies (against MC1-R, ABCG1, Mac-2, or CD68) and subsequently with a horseradish peroxidase-conjugated secondary antibody and diaminobenzidine (ABC kit; Vector Labs) or with fluorochrome-conjugated secondary antibodies.
Flow Cytometry
Aorta, spleen, bone marrow, and blood samples from ApoE −/− mice were used for quantification of leukocyte subsets by flow cytometry. After preparation of single-cell suspensions, cells were stained with fluorochrome-conjugated antibodies against CD45.2 (clone 104), CD11b (clone M1/70), CD115 (clone AFS98), F4/80 (clone BM8), Ly6C (clone AL-21), and Ly6G (clone 1A8) and were measured by FACS Canto II flow cytometer.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 5 (GraphPad Software Inc) or R version 3.1.1 (http://www.rproject.org/). For comparisons of MC1-R expression in human samples, log-transformed data and the nonparametric Mann-Whitney U test were used. Pearson or nonparametric Spearman correlation coefficients were calculated for gene associations based on D'Agostino-Pearson omnibus normality test results. For mouse data, the Student t test, Mann-Whitney U test, or 1-way ANOVA was used to determine statistical significance. For 2 independent factors, 2-way ANOVA was used followed by Bonferroni post hoc tests. Possible outliers in the data sets were detected with the robust regression and outlier removal method at a Q level of 5%. All data are presented as mean±SEM. A 2-tailed value of P<0.05 was considered statistically significant.
RESULTS

Human and Mouse Atherosclerotic Plaques Express MC1-R in MacrophageRich Areas
We first screened the expression of melanocortin receptor subtypes in human endarterectomy samples and compared the transcript levels to atherosclerosis-free control arteries (left internal thoracic artery). Strikingly, MC1-R was the only subtype that showed consistent and highly significant expression changes in different types of endarterectomy samples compared with controls (Table II in the online-only Data Supplement). MC1-R was markedly upregulated (fold change, 1.7; P=1.3e-11) in atherosclerotic plaques ( Figure 1A ), but the expression did not differ between stable and unstable plaque types ( Figure 1B) . The expression of MC1-R in endarterectomy samples was further confirmed with immunohistochemical stainings ( Figure 1C and 1D) , which also revealed that MC1-R staining merged with CD68-positive area ( Figure 1D We further sought to investigate the expression pattern of MC1-R in atherosclerotic lesions and in other tissues of ApoE −/− mice at different stages of the disease. Shifting from normal chow diet to atherogenic HFD caused a robust upregulation of MC1-R expression in the aorta after 4 weeks of HFD, which then declined toward a more advanced stage of atherosclerosis (Figure 2A ). This expression pattern might not be simply explained by the accumulation of macrophages within the aortic wall because macrophages also represent the predominant cell type at advanced plaque stage. Thus, we hypothesized that a shift in macrophage phenotype might lead to a change in MC1-R expression. In vitro experiments with BMDMs indeed revealed lower protein levels of MC1-R when macrophages were polarized with IL-4 or dexamethasone into an M2 phenotype ( Figure IIA in the online-only Data Supplement). However, MC1-R protein levels were unaffected by exposure to increasing doses of either native LDL or oxLDL ( Figure  IIB in the online-only Data Supplement), the latter of which is demonstrated to induce an alternative macrophage phenotype. 21 Plaque macrophages are thought to originate from circulating monocytes that are mobilized from bone marrow and spleen. 22, 23 We therefore assessed potential changes in MC1-R expression in these organs and observed a drastic decrease in splenic MC1-R expression after 4 weeks of HFD followed by a partial recovery at 16 weeks of HFD ( Figure 2B ). Bone marrow MC1-R expression showed an increasing trend in association with the duration of the HFD ( Figure 2C ), which might be explained by enhanced myelopoiesis and thus number of MC1-R-expressing monocytes resulting from the hypercholesterolemia.
The aortic MC1-R gene expression pattern was further supported by immunofluorescence, which showed the strongest MC1-R staining in the lesions of mice fed an HFD for 4 weeks colocalizing in macrophage-rich areas ( Figure 2D ). In line with the human data, MC1-R expression was directly associated with ABCA1 and ABCG1 mRNA levels in the aorta of mice fed an HFD for 4 weeks ( Figure 2E and 2F), whereas no significant association to SR-BI ( Figure 2G ), CD36, or SR-A (data not shown) was observed.
The Endogenous MC1-R Agonist α-MSH Inhibits Cholesterol Uptake and Increases Cholesterol Efflux in Macrophages
Given the association of MC1-R expression with regulators of reverse cholesterol transport, we further aimed to investigate the role of MC1-R in macrophage cholesterol metabolism. To this end, we loaded BMDMs with [ 3 H]-cholesterol before treatment with the natural MC1-R agonist α-MSH to measure cholesterol efflux onto the lipid acceptors ApoA1 or HDL. We found that α-MSH significantly increased efflux capacity to HDL without affecting cholesterol efflux to ApoA1 ( Figure 3A ), potentially reflecting an alteration in ABCG1 or SR-BI expression. As an additional protective mechanism against foam cell formation, α-MSH reduced the uptake of ox-LDL after a short-term treatment but failed to sustain this effect when the oxLDL loading was performed after 24 hours of α-MSH stimulation ( Figure 3B ). To address the molecular mechanisms behind these effects, we quantified the protein levels of key mediators of cho-ORIGINAL RESEARCH ARTICLE lesterol efflux (ABCA1, ABCG1, and SR-BI) and uptake (CD36 and SR-A) after 24-hour treatment with α-MSH. Consistent with the functional efflux data, α-MSH increased ABCG1 protein levels and caused a biphasic response in ABCA1 expression with declining levels after high concentrations of α-MSH ( Figure 3C and Figure  IIIA in the online-only Data Supplement). α-MSH also elevated CD36 expression ( Figure 3C and Figure IIIA in the online-only Data Supplement), which accounts for ≈50% of cholesterol uptake in macrophages and therefore contradicts the finding of reduced oxLDL uptake in α-MSH-treated macrophages. To clarify this discrepancy, we determined cell surface expression of CD36 by flow cytometry after short-term α-MSH stimulation and found that α-MSH markedly reduced membrane-associated CD36 ( Figure 3D and 3E) , thereby also interfering with oxLDL-induced internalization of CD36 ( Figure 3F ). This effect was lost after 24-hour stimulation with α-MSH ( Figure IIIB in the online-only Data Supplement). Despite the increase of total CD36 expression, observed by Western blotting, oxLDL uptake was not augmented by α-MSH, indicating that the effect on CD36 surface expression is the dominant factor determining cholesterol uptake of α-MSH-treated macrophages. Because SR-BI level has an inverse relationship with cellular cholesterol pools, 24 we loaded BMDMs with oxLDL and 
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assayed them for SR-BI to further investigate whether α-MSH is capable of preventing cholesterol accumulation. Of note, α-MSH attenuated the oxLDL-induced reduction of SR-BI ( Figure 3G ). Last, because ABCA1 and ABCG1 transporters have been reported to control leukocytosis, 25, 26 we assessed the proliferation rate of α-MSH-treated BMDMs, revealing that the amount of cells in active G1 phase was reduced by α-MSH (Figure 3I and 3J) . Collectively, these results indicate that α-MSH enhances cholesterol efflux onto HDL and inhibits CD36-mediated lipid uptake in macrophages while limiting macrophage proliferation.
Selective MC1-R Agonists Mimic the Effects of α-MSH
Because the natural ligand α-MSH does not only bind to MC1-R, we next tested whether selective MC1-R ag- onists evoke similar effects in BMDMs. We used LD211 and MSG606, which have been shown to have high affinity for MC1-R with no or only minimal binding to other MC-R subtypes. 16, 27 In BMDMs, LD211 acted like a classic agonist, causing a strong response in cAMP assay, whereas MSG606 reduced intracellular cAMP concentration, a characteristic of an inverse agonist ( Figure  IVA and IVB in the online-only Data Supplement). Furthermore, both agonists were able to engage other signaling cascades, namely phosphorylation of extracellular signal-regulated kinase 1/2 and dephosphorylation of p38 mitogen-activated protein kinase, in a time-and dose-dependent manner ( Figure IVC through IVF in the online-only Data Supplement). Of note, MSG606 had a stronger effect on extracellular signal-regulated kinase 1/2 phosphorylation compared with LD211 ( Figure IVE in the online-only Data Supplement). In terms of the signaling responses, the maximal effects were reached in the micromolar range. We therefore used micromolar concentrations of these compounds for subsequent experiments.
First, we characterized the potential anti-inflammatory effects of these compounds in lipopolysaccharidestimulated BMDMs. LD211 showed only modest suppression of cytokine mRNA expression and secretion with preferential effects on IL-6 and chemokine C-C motif ligand 2 ( Figure V in the online-only Data Supplement). MSG606 caused somewhat divergent effects and selectively reduced the mRNA expression of IL-1β and TNFα (Figure VI in the online-only Data Supplement). Overall, the anti-inflammatory effects of the agonists were weak and comparable to those of α-MSH.
Second, the effects on cholesterol transporter proteins were investigated, demonstrating that selective MC1-R agonists such as α-MSH increase ABCA1 and ABCG1 protein levels ( Figure 4A ). MSG606 showed no other effects, whereas LD211 caused reductions in SR-BI and SR-A levels and an increase in CD36 expression ( Figure 4A ). To investigate the mechanism behind increased ABCA1 and ABCG1 protein, we first quantified mRNA expression and found that both compounds upregulated ABCA1 and ABCG1 without affecting liver X receptor-α (LXRα), which is one of the strongest inducers of ABCA1 and ABCG1 ( Figure 4C ). We also assessed whether MC1-R activation regulates the expression of other LXRα target genes such as ApoE. Both agonists were devoid of a systemic effect on the analyzed target genes except for cholesterol 7 α-hydoxylase (Figure VII in the online-only Data Supplement), which was specifically upregulated on treatment. Cholesterol 7 α-hydoxylase is involved in cholesterol catabolism and might help macrophages to maintain cholesterol homeostasis. 28 Because ABCA1 and ABCG1 expression is strongly regulated by diverse posttranscriptional mechanisms, we conducted additional experiments to determine whether MC1-R activation influences mRNA or protein stability of these transporters. Blocking transcription with actinomycin D revealed that mRNA stability of ABCA1 and ABCG1 was unchanged after 4-hour (data not shown) or 24-hour treatment with LD211 or MSG606 (Figure VIII in the online-only Data Supplement). Furthermore, these compounds did not increase the stability of ABCA1 protein ( Figure IX in the online-only Data Supplement). Given that miRNAs have recently emerged as critical regulators of ABCA1 and ABCG1, 29, 30 we next explored whether MC1-R activation modulates the expression of miRNAs that are known to target and repress these transporters. However, LD211 and MSG606 had no consistent effects on the expression of miRNAs such as miR-33, miR-148a, and miR-758 ( Figure X in the online-only Data Supplement), excluding the possibility that miRNAs are primarily driving the observed effects. Taken together, the data suggest that the upregulation of ABCA1 and ABCG1 protein is attributable mainly to transcriptional induction.
It is important to note that the upregulation of ABCA1 and ABCG1 transporters translated functionally into enhanced cholesterol efflux to both ApoA1 and HDL ( Figure 4D ). In line with the effects of α-MSH, selective agonism of MC1-R acutely reduced the cell surface expression of CD36 and attenuated cholesterol uptake ( Figure 4E and 4F ). BMDMs were also loaded with oxLDL and then quantified for LXRα expression as a sensitive marker of cholesterol influx. LD211 and MSG606 effectively attenuated the oxLDL-induced increase in LXRα expression ( Figure 4G ). Similar to α-MSH, these compounds were able to restore the SR-BI levels in the oxLDL-loaded state ( Figure 4H and 4I) , providing further evidence that MC1-R activation prevents lipid accumulation. Proliferation of BMDMs was also reduced by treatment with MSG606 but not with LD211 ( Figure 4J ). These data suggest that MC1-R is responsible for the observed effects of α-MSH on macrophage cholesterol transport.
Macrophages Deficient in Functional MC1-R Display Enhanced Cholesterol Uptake and Reduced Efflux Capacity
To investigate whether loss of function of MC1-R in macrophages translates into a reverse phenotype compared with MC1-R activation, we isolated BMDMs from mice deficient in functional MC1-R signaling (MC1-R e/e ) and their wild-type littermates and determined first the cholesterol accumulation in these cells. Indeed, MC1-R e/e macrophages showed increased uptake of Dil-oxLDL ( Figure 5A ) and higher proportion of Oil Red O-positive cells after oxLDL loading (Figure 5B) . At the molecular level, MC1-R e/e BMDMs had an augmented LXRα ex-ORIGINAL RESEARCH ARTICLE pression in response to oxLDL ( Figure 5C ). In agreement with increased cholesterol uptake, we observed higher cell surface and mRNA levels of CD36 in MC1-R e/e macrophages ( Figure 5D and 5F). Functionally, MC1-R-deficient BMDMs also displayed reduced cholesterol efflux onto ApoA1 and HDL compared with wild-type BMDMs ( Figure 5E ). Consistent with the reduced efflux onto ApoA1, ABCA1 mRNA expression was lower in MC1-R e/e macrophages ( Figure 5F ). Gene expression data also showed less SR-BI but unchanged ABCG1 levels in MC1-R e/e ( Figure 5F ). However, Western blot analysis revealed reduced ABCG1 protein expression under baseline conditions, which might partly account for the impaired efflux rate onto HDL ( Figure 5G and 5H) .
In addition to cholesterol metabolism, we determined the expression of proinflammatory and antiinflammatory markers in MC1-R e/e macrophages under baseline and stimulated conditions. Unexpectedly, deficient MC1-R signaling was associated with reduced mRNA levels of proinflammatory M1 markers IL-1β and TNFα in unstimulated conditions and with suppressed IL-1β and IL-6 response to lipopolysaccharide ( Figure XI in the online-only Data Supplement). However, ELISA analysis revealed that release of these cytokines was un- −/− mice with MSG606 had no effect on body weight gain (data not shown), but it significantly reduced total cholesterol levels in the plasma compared with the control group ( Figure 6A ). This reduction was evenly distributed in the very-low-density lipoprotein and LDL fractions ( Figure 6B ), which retain ≈95% of the total plasma cholesterol in ApoE −/− mice. The total plaque area at the level of the aortic sinus and lesional macrophage coverage as judged by relative Mac-2-positive area of aortic root sections were not affected by MSG606 (Figure 6C through 6E) . However, gene expression analysis of aortic lysates revealed significantly reduced CD36 mRNA levels in MSG606-treated mice and increased expression of collagen (Col1A2 and Col3A1) and α-smooth muscle actin, which are markers of plaque stability ( Figure 6F and 6G) . Masson trichrome staining of aortic root sections further evidenced higher collagen content in the lesions of MSG606-treated mice ( Figure 6H and 6I) . Because the gene expression analysis of whole aortas did not reveal significant changes of ABCG1 mRNA levels, we further aimed e/e BMDMs. G and H, Representative Western blots for ABCA1, ABCG1, and GAPDH (loading control) and quantification of ABCG protein levels in WT and MC1R
e/e BMDMs under control conditions and after oxLDL loading (20 μg/mL, 24 hours). Data are mean±SEM from 4 donor mice per genotype. *P<0.05 and **P<0.01 vs WT.
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to quantify ABCG1 expression specifically in plaque macrophages by double immunofluorescence. Indeed, we found more pronounced ABCG1 staining in mice colocalizing with plaque macrophages (Figure 6J and 6K), thereby extending our in vitro findings on reverse cholesterol transporters into an in vivo setting.
To investigate other contributing factors for the reduced plasma cholesterol, we first analyzed the expression of cholesterol transport and synthesis genes in the liver. MSG606 treatment increased hepatic ABCA1 and ABCG1 and LDL receptor mRNA levels without affecting the expression of cholesterol synthesis genes ( Figure  XII We also performed flow cytometry analyses of the aorta, blood, spleen, and bone marrow of treated ApoE −/− mice to assess potential differences in leukocyte subsets ( Figure 7A ). Despite the fact that Mac-2 immunohistochemistry revealed no signs of treatment effect, MSG606-treated mice had less Ly6C high monocytes in the aorta ( Figure 7B ), and circulating monocyte counts were higher ( Figure 7C through 7E) . We may speculate that the decrease in Ly6C high monocyte counts in aortas of MSG606-treated mice might be due 
DISCUSSION
Several lines of evidence indicate that MC1-R activation in macrophages is functionally linked to anti-inflammatory modulation and proresolving properties, 1 but the present findings unveil a completely new aspect of MC1-R biology. A series of in vitro experiments demonstrated that triggering MC1-R signaling either with its natural ligand α-MSH or synthetic MC1-R agonists protects macrophages against excessive cholesterol accumulation and foam cell formation. This finding is likely explained by 2 main factors. First, MC1-R activation downregulated the expression of cell surface CD36, which belongs to the scavenger receptor family and interacts with multiple ligands, including oxLDL. 31 Given that CD36 significantly contributes to foam cell formation and promotes atherosclerosis, 31, 32 the inhibition of CD36-mediated oxLDL uptake by MC1-R is likely ORIGINAL RESEARCH ARTICLE to be atheroprotective. The exact molecular mechanism for CD36 downregulation on MC1-R activation is unknown, but it is driven by a cAMP-independent signaling cascade because MSG606 evoked a similar response to α-MSH. Second, we identified that MC1-R activation strongly enhances cholesterol efflux onto both ApoA1 and HDL through LXRα-independent upregulation of ABCA1 and ABCG1 expression. The effects of α-MSH and selective MC1-R agonists were for the most part consistent except for small differences such as the lack of effect of α-MSH on ABCA1-mediated cholesterol efflux. In the case of α-MSH, the interpretation of the results is complicated by its agonistic activity at the melanocortin 3 receptor, which is abundantly expressed by macrophages. 9 Furthermore, α-MSH is naturally produced and released by macrophages, and thus, treating cells with supraphysiological concentrations of α-MSH might disturb the autocrine/paracrine signaling of the α-MSH/MC1-R axis and lead to unexpected responses. 5, 33 In good agreement with our findings on MC1-R agonism, we found that dysfunctional MC1-R in macrophages was associated with a reverse phenotype, namely enhanced cholesterol uptake and disturbed efflux machinery. Surprisingly, MC1-R-deficient macrophages were devoid of a proinflammatory phenotype, which was expected to appear on the basis the previous and present findings that stimulation of MC1-R exerts anti-inflammatory actions. On the other hand, we noted that cytokine expression was only modestly suppressed by MC1-R activation compared with the much stronger effects on cholesterol transport. These results are in line with a previous notion that MC1-R is not the dominant receptor subtype in mediating the antiinflammatory actions of melanocortin peptides in murine macrophages. 7 In contrast, the present data clearly illustrate that MC1-R carries a nonredundant role in the regulation of cholesterol transport.
To further explore the concept of MC1-R-mediated regulation of cholesterol transport and its translation into therapeutic effectiveness in vivo, atherosclerotic ApoE −/− mice were treated long term with MSG606. This compound was selected for in vivo testing mainly for 2 reasons. First, MSG606 showed superior potency to LD211 in terms of harnessing protective mechanisms against foam cell formation. Second, from a drug development perspective, biased agonism, which is pathway selective, is an emerging concept with significant therapeutic interest. 34 We found that MSG606 acts like a biased agonist by promoting extracellular signal-regulated kinase but not cAMP signaling. With this kind of compound, it is possible to target only the therapeutically important pathways and to avoid activating pathways that lead to side effects. In the case of MC1-R biology, melanogenesis is evoked by cAMP formation, and thus, dissociating this pathway prevents the unwanted pigmentary effects. Biased agonism of MC1-R and melanocortin 3 receptor with a small molecule, AP1189, has been proven recently to be a viable approach for suppressing inflammation in conditions such as peritonitis and arthritis. 35 Here, we were able to further validate this concept and to prove its applicability in a different biological context. By targeting MC1-R for the treatment of atherosclerosis, we aimed to build on the paradigm that efficient cholesterol efflux from macrophages, through maintained integrity of ABCA1 and ABCG1 transporters, is atheroprotective. 36 However, although strongly promoting cholesterol efflux in cultured BMDMs and showing similar responses at the molecular level in vivo combined with a cholesterol-lowering effect, MSG606 did not limit plaque size in ApoE −/− mice. This might be due to several reasons. First, the pharmacokinetic properties of MSG606 have not been previously evaluated; hence, it is unknown whether the selected dose and frequency of drug administration were sufficient. Second, we observed that lesional MC1-R expression localized to a distinct and limited subset of macrophages, which raises the question of whether activation of this restricted population is effective enough to confer protection against plaque development. Third, previous studies using transgenic models of ABCA1 and ABCG1 overexpression on an ApoE −/− background have failed to demonstrate atheroprotective effects. 37, 38 The absence of ApoE lowers the plasma levels of ApoA1 and HDL and impairs cholesterol efflux from macrophages, which might neutralize the effectiveness of drugs that are acting on cholesterol efflux transporters. And finally, the atheroprotective effect linked to improved cholesterol metabolism might be more pronounced at more advanced plaque stage. Therefore, further experiments are warranted to determine whether modified dosing and treatment timing of the MSG606 therapy or alternative ways to target the MC1-R could eventually halt the development of atherosclerotic plaques or even lead to regression of existing plaques in a different atherosclerosis model. Nevertheless, MSG606 treatment promoted signs of plaque stability, indicating that it favorably tunes the balance between collagen synthesis and breakdown through an as-yet unknown mechanism. Furthermore, we found that MSG606 reduced arterial monocyte accumulation with a concomitant increase in circulating Ly6C low monocytes. It is noteworthy that these changes occurred without induction of myelopoiesis. The underlying mechanism for this is likely to be multifactorial, involving downregulation of adhesion molecule and cytokine expression in both monocytes and endothelial cells. This notion is supported by previous findings demonstrating that MC1-R activation inhibits monocyte adhesion to inflamed vasculature. 39, 40 Importantly, these results provide evidence that MC1-R activation in vivo promotes advantageous changes in plaque architecture.
CONCLUSIONS
Our findings uncover a novel role for MC1-R in macrophage cholesterol transport that is independent of cAMP signaling. Triggering MC1-R signaling in macrophages suppresses cholesterol uptake and promotes reverse cholesterol transport, which are preventive mechanisms against foam cell formation and the progression of atherosclerosis.
